Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic triple-negative breast cancer.
EP. 1: A Brief Overview of Treatment Options for Triple-Negative Breast Cancer
Expert oncologist Aditya Bardia, MD, MPH, shares his perspective on mainstay treatment options for patients diagnosed with metastatic triple-negative breast cancer.
EP. 2: Patient Scenario: A 44-Year-Old Woman With Metastatic TNBC
Centering discussion on a patient scenario of metastatic TNBC, Aditya Bardia, MD, MPH, highlights the value of first-line chemoimmunotherapy as a treatment option.
EP. 3: First-Line Treatment for Metastatic TNBC: Pembrolizumab + Chemotherapy
Comprehensive insight on use of first-line pembrolizumab plus chemotherapy in patients diagnosed with metastatic TNBC based on results from the KEYNOTE-355 trial.
EP. 4: Future Treatment Strategies for Triple-Negative Breast Cancer
Closing out his discussion on the management of metastatic triple-negative breast cancer, Aditya Bardia, MD, MPH, considers future treatment strategies that may improve outcomes for patients.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer